Science Publishing Group: Journal of Cancer Treatment and Research: Table of Contents
<i> Journal of Cancer Treatment and Research (JCTR) </i> provides a forum for the publication of scientific research and review articles. The journal publishes original full-length research papers in all areas related to cancer treatment and research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. It aims to impart highly relevant and timely information to a broad audience of oncology and related specialists in the field.
http://www.sciencepublishinggroup.com/j/jctr Science Publishing Group: Journal of Cancer Treatment and Research: Table of Contents
Science Publishing Group
en-US
Journal of Cancer Treatment and Research
Journal of Cancer Treatment and Research
http://image.sciencepublishinggroup.com/journal/654.gif
http://www.sciencepublishinggroup.com/j/jctr
Diagnosis and Treatment of Head and Neck Sarcomas: Personal Experiences
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20130101.11
Sarcomas are a rare group of tumors. They do not commonly manifest as malignancies in the head and neck region. The rare nature of these tumors has resulted in a limited number of publications. This is a descriptive study. We included patients with primary sarcomas of the head and neck, observed between 1991 and 2011 in the department of Otorhinolaryngology (University of Chieti, Italy). We studied the following variables: age, gender, race, origin, primary anatomical location of the neoplasm, pathology, diagnosis and type of cancer treatment employed. During the study period, we found 9 patients with head and neck sarcomas. Of this sample, 6 were males, and 3 were females. The man/woman ratio was 2:1. As far as age is concerned, the most affected age range was between 60 and 80 years. The mean age of the patients was 62. As far as pathology is concerned, we found 7 histopathological variations of sarcomas, and the most common type was the leiomyosarcoma. The most widely used treatment modality was surgical treatment. The data in this study show that head and neck sarcomas are rare tumors with high histological variability, which may involve different anatomical sites. Since these are rare and not well-known lesions, further epidemiological studies must be carried out, in order to give us more knowledge about the disease.
Sarcomas are a rare group of tumors. They do not commonly manifest as malignancies in the head and neck region. The rare nature of these tumors has resulted in a limited number of publications. This is a descriptive study. We included patients with primary sarcomas of the head and neck, observed between 1991 and 2011 in the department of Otorhinolaryngology (University of Chieti, Italy). We studied the following variables: age, gender, race, origin, primary anatomical location of the neoplasm, pathology, diagnosis and type of cancer treatment employed. During the study period, we found 9 patients with head and neck sarcomas. Of this sample, 6 were males, and 3 were females. The man/woman ratio was 2:1. As far as age is concerned, the most affected age range was between 60 and 80 years. The mean age of the patients was 62. As far as pathology is concerned, we found 7 histopathological variations of sarcomas, and the most common type was the leiomyosarcoma. The most widely used treatment modality was surgical treatment. The data in this study show that head and neck sarcomas are rare tumors with high histological variability, which may involve different anatomical sites. Since these are rare and not well-known lesions, further epidemiological studies must be carried out, in order to give us more knowledge about the disease.
Diagnosis and Treatment of Head and Neck Sarcomas: Personal Experiences
doi:10.11648/j.jctr.20130101.11
Journal of Cancer Treatment and Research
2014-01-01
© Science Publishing Group
Melissa Laus
Domenico Crescenzi
Antonio Moretti
Adelchi Croce
Diagnosis and Treatment of Head and Neck Sarcomas: Personal Experiences
1
1
7
7
2014-01-01
2014-01-01
10.11648/j.jctr.20130101.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20130101.11
© Science Publishing Group
Current Thinking on Malignant Salivary Gland Neoplasms
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20130101.12
Malignant salivary gland neoplasms are rare, representing approximately 3% to 7% of all head and neck cancers. Contrasting from the more common mucosal head and neck cancers, which, in general, are ascribed to excessive tobacco, alcohol use, and more recently to viral infection, specific carcinogenic factors for malignant salivary gland growths have not been as clearly identified. Histologically, they represent a heterogeneous group of tumors. Forty histologic types of epithelial tumors of the salivary glands have been reported; some are exceedingly rare and may be the topic of only a few case reports. Salivary tumors can arise in the major salivary glands or in one of the minor salivary glands (predominantly mucus secreting glands), which are distributed throughout the upper aerodigestive. Most patients who develop malignant salivary gland tumors are in the sixth or seventh decade of life. FNA should be considered as part of the diagnostic evaluation but due to its varying sensitivities and specificities imaging modalities such as ultrasound, CT scans, and MRI should also be used as diagnostic adjuncts. Surgery is the primary modality for management of these tumors, nontraditional surgical approaches and instrumentation, as well as facial nerve monitoring, can be selectively utilized to try and decrease the morbidity associated with these surgical procedures. Adjuvant treatment is primarily achieved with radiation therapy. Chemotherapy continues to have a palliative role in the management of salivary gland tumors; however, research in this field is trying to identify a therapeutic role for chemotherapy in order to improve overall survival.
Malignant salivary gland neoplasms are rare, representing approximately 3% to 7% of all head and neck cancers. Contrasting from the more common mucosal head and neck cancers, which, in general, are ascribed to excessive tobacco, alcohol use, and more recently to viral infection, specific carcinogenic factors for malignant salivary gland growths have not been as clearly identified. Histologically, they represent a heterogeneous group of tumors. Forty histologic types of epithelial tumors of the salivary glands have been reported; some are exceedingly rare and may be the topic of only a few case reports. Salivary tumors can arise in the major salivary glands or in one of the minor salivary glands (predominantly mucus secreting glands), which are distributed throughout the upper aerodigestive. Most patients who develop malignant salivary gland tumors are in the sixth or seventh decade of life. FNA should be considered as part of the diagnostic evaluation but due to its varying sensitivities and specificities imaging modalities such as ultrasound, CT scans, and MRI should also be used as diagnostic adjuncts. Surgery is the primary modality for management of these tumors, nontraditional surgical approaches and instrumentation, as well as facial nerve monitoring, can be selectively utilized to try and decrease the morbidity associated with these surgical procedures. Adjuvant treatment is primarily achieved with radiation therapy. Chemotherapy continues to have a palliative role in the management of salivary gland tumors; however, research in this field is trying to identify a therapeutic role for chemotherapy in order to improve overall survival.
Current Thinking on Malignant Salivary Gland Neoplasms
doi:10.11648/j.jctr.20130101.12
Journal of Cancer Treatment and Research
2014-01-01
© Science Publishing Group
Rodrigo Arrangoiz
Pavlos Papavasiliuo
David Sarcu
Thomas J. Galloway
John A. Ridge
Miriam Lango
Current Thinking on Malignant Salivary Gland Neoplasms
1
1
24
24
2014-01-01
2014-01-01
10.11648/j.jctr.20130101.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20130101.12
© Science Publishing Group
Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140201.12
Chitotriosidase is synthesized and secreted especially in activated macrophages. The aim of this study was to evaluate chitotriosidase activity in patients with various stages of hepatitis C. The study included a total of 90 patients. The patients were divided into four groups. Group 1 included 54 patients with chronic active hepatitis, Group 2 included 20 patients with recovered HCV, Group 3 included 6 patients with HCV induced hepatocellular carcinoma, and Group 4 included 10 patients with HCV cirrhosis. Chitotriosidase activity was measured with spectrophotometry (SigmaAldrich ®). The mean chitotriosidase activity of the four groups was 0,927u/L (0.804u/L in Group 1, 0.521u/L in Group 2, 3.211u/L in Group 3 and 1.030u/L in Group 4). Chitotriosidase activity was significantly higher in Group 3. ROC analysis, used to evaluate chitotriosidase activity for the diagnosis of hepatocellular carcinoma, showed that chitotriosidase activity of 0,935 was below the curve (CI: 95%; 0,862 - 0,976), which was statistically significant (p= 0,0001). The cut-off value was >1,098 with a sensitivity of 100% and a specifity of 81%. Chitotriosidase activity can be a marker with a high sensitivity and specifity for the diagnosis of hepatocellular carcinoma.
Chitotriosidase is synthesized and secreted especially in activated macrophages. The aim of this study was to evaluate chitotriosidase activity in patients with various stages of hepatitis C. The study included a total of 90 patients. The patients were divided into four groups. Group 1 included 54 patients with chronic active hepatitis, Group 2 included 20 patients with recovered HCV, Group 3 included 6 patients with HCV induced hepatocellular carcinoma, and Group 4 included 10 patients with HCV cirrhosis. Chitotriosidase activity was measured with spectrophotometry (SigmaAldrich ®). The mean chitotriosidase activity of the four groups was 0,927u/L (0.804u/L in Group 1, 0.521u/L in Group 2, 3.211u/L in Group 3 and 1.030u/L in Group 4). Chitotriosidase activity was significantly higher in Group 3. ROC analysis, used to evaluate chitotriosidase activity for the diagnosis of hepatocellular carcinoma, showed that chitotriosidase activity of 0,935 was below the curve (CI: 95%; 0,862 - 0,976), which was statistically significant (p= 0,0001). The cut-off value was >1,098 with a sensitivity of 100% and a specifity of 81%. Chitotriosidase activity can be a marker with a high sensitivity and specifity for the diagnosis of hepatocellular carcinoma.
Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma
doi:10.11648/j.jctr.20140201.12
Journal of Cancer Treatment and Research
2014-01-01
© Science Publishing Group
Engin ALTINTAS
Serkan Yaras
Burak CIMEN
Enver UCBILEK
Bunyamin SARITAS
Fehmi ATES
Orhan SEZGIN
Gulhan OREKECI
Chitotriosidase Activity in Different Stages of Hepatitis C. It may a Possible Tumor Marker for Hepatocellular Carcinoma
2
1
8
8
2014-01-01
2014-01-01
10.11648/j.jctr.20140201.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140201.12
© Science Publishing Group
Limitation of Pencil Beam Convolution (PBC) Algorithm for Photon Dose Calculations in Inhomogeneous Medium
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140201.11
Purpose: The main purpose of this study is to investigate the accuracy of pencil beam convolution (PBC) algorithm when high-density inhomogeneity is involved along the photon beam path. This study will help the PBC users understand the limitation of PBC during the treatment planning of real cancer treatment plans, especially when tumor is located beyond high-density tissue such as bone. Methods: Inhomogeneous phantom (30 cm x 30 cm, 17 cm deep) with a 5 cm thick solid water as the top layer followed by 5 cm thick PVC and 7 cm solid water was manufactured for depth dose calculations and measurements. Data were obtained beyond PVC medium for three field sizes: 5 x 5 cm2, 10 x 10 cm2, and 20 x 20 cm2. Dose calculations were performed using PBC and measurements were done using chamber. Measured and calculated data were compared against each other. Results: PBC produced dose prediction errors beyond high density medium by 3.7% to 7.3% for field size 5 x 5 cm2, by 4.8% to 6.9% for field size 10 x 10 cm2, and by 5.9% to 7.3% for field size 20 x 20 cm2. The results of this study, however, showed no clear dependency on the field size. Similarly, difference between the PBC and measurements did not show a clear trend when results at various points were compared with each other. Conclusion: PBC can overestimate the dose by up to 7.3% beyond high-density medium. High density materials such metallic immobilization devices must be avoided in the beam path during the patient treatment.
Purpose: The main purpose of this study is to investigate the accuracy of pencil beam convolution (PBC) algorithm when high-density inhomogeneity is involved along the photon beam path. This study will help the PBC users understand the limitation of PBC during the treatment planning of real cancer treatment plans, especially when tumor is located beyond high-density tissue such as bone. Methods: Inhomogeneous phantom (30 cm x 30 cm, 17 cm deep) with a 5 cm thick solid water as the top layer followed by 5 cm thick PVC and 7 cm solid water was manufactured for depth dose calculations and measurements. Data were obtained beyond PVC medium for three field sizes: 5 x 5 cm2, 10 x 10 cm2, and 20 x 20 cm2. Dose calculations were performed using PBC and measurements were done using chamber. Measured and calculated data were compared against each other. Results: PBC produced dose prediction errors beyond high density medium by 3.7% to 7.3% for field size 5 x 5 cm2, by 4.8% to 6.9% for field size 10 x 10 cm2, and by 5.9% to 7.3% for field size 20 x 20 cm2. The results of this study, however, showed no clear dependency on the field size. Similarly, difference between the PBC and measurements did not show a clear trend when results at various points were compared with each other. Conclusion: PBC can overestimate the dose by up to 7.3% beyond high-density medium. High density materials such metallic immobilization devices must be avoided in the beam path during the patient treatment.
Limitation of Pencil Beam Convolution (PBC) Algorithm for Photon Dose Calculations in Inhomogeneous Medium
doi:10.11648/j.jctr.20140201.11
Journal of Cancer Treatment and Research
2014-01-01
© Science Publishing Group
Tesering Dorje
Limitation of Pencil Beam Convolution (PBC) Algorithm for Photon Dose Calculations in Inhomogeneous Medium
2
1
4
4
2014-01-01
2014-01-01
10.11648/j.jctr.20140201.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140201.11
© Science Publishing Group
Colour Doppler-An Evaluation Tool for Assessment of Breast Tumour Size, Axillary Lymph Node Size and Chemotherapeutic Response
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140202.11
Aims: The present study was taken up in carcinoma breast patients to evaluate clinical examination and Colour Doppler in estimating the breast tumour size, axillary lymph node size and chemotherapeutic response, taking histopathological examination as the gold standard. Material & Methods: The study carried out between December 2008 to June 2010 included 37 patients. Ethics committee clearance obtained. Chemotherapeutic response could be assessed in 24 patients who received chemotherapy prior to surgery. 13 patients were taken up directly for surgery. Clinical, sonological and histopathological largest dimension of the primary tumour and axillary lymph nodes were assessed. Chemotherapy response grades were assessed as per criteria given by Kumar A et al. Results were analyzed using paired-t test, weighted kappa and Spearman correlation coefficient. Results: The difference between mean clinical and histopathological size of breast tumour of 0.01cm, was statistically not significant (t=.064, p=.949). However, the difference between mean sonological and histopathological size of breast tumour of 1.10cm, was statistically highly significant (t=-3.93, p<.001). For axillary lymph nodes, the mean difference between clinical and histopathological assessment was 0.46 cm (p=0.007) as against mean difference of 0.48 cm between sonological and histopathological assessment (p=0.001). Clinical response showed substantial agreement with histopathological response in breast tumour (k=0.657; p=0.001) and axillary lymph nodes (k=0.62; p<0.005). Sonological response showed moderate agreement (k=0.510; p< 0.02) in breast tumour and substantial agreement (k=0.691; p<0.001) in axillary lymph nodes. Compared to histopathological response, RI, PI and Vmax response showed moderate agreement in primary and substantial agreement in axillary lymph nodes. Conclusion: In the present study, sonology was found to be a poor modality for breast tumour size, axillary lymph node size estimation. With regard to chemotherapy response assessment, clinical examination was a better modality for primary, while Colour Doppler was better for axillary lymph node evaluation.
Aims: The present study was taken up in carcinoma breast patients to evaluate clinical examination and Colour Doppler in estimating the breast tumour size, axillary lymph node size and chemotherapeutic response, taking histopathological examination as the gold standard. Material & Methods: The study carried out between December 2008 to June 2010 included 37 patients. Ethics committee clearance obtained. Chemotherapeutic response could be assessed in 24 patients who received chemotherapy prior to surgery. 13 patients were taken up directly for surgery. Clinical, sonological and histopathological largest dimension of the primary tumour and axillary lymph nodes were assessed. Chemotherapy response grades were assessed as per criteria given by Kumar A et al. Results were analyzed using paired-t test, weighted kappa and Spearman correlation coefficient. Results: The difference between mean clinical and histopathological size of breast tumour of 0.01cm, was statistically not significant (t=.064, p=.949). However, the difference between mean sonological and histopathological size of breast tumour of 1.10cm, was statistically highly significant (t=-3.93, p<.001). For axillary lymph nodes, the mean difference between clinical and histopathological assessment was 0.46 cm (p=0.007) as against mean difference of 0.48 cm between sonological and histopathological assessment (p=0.001). Clinical response showed substantial agreement with histopathological response in breast tumour (k=0.657; p=0.001) and axillary lymph nodes (k=0.62; p<0.005). Sonological response showed moderate agreement (k=0.510; p< 0.02) in breast tumour and substantial agreement (k=0.691; p<0.001) in axillary lymph nodes. Compared to histopathological response, RI, PI and Vmax response showed moderate agreement in primary and substantial agreement in axillary lymph nodes. Conclusion: In the present study, sonology was found to be a poor modality for breast tumour size, axillary lymph node size estimation. With regard to chemotherapy response assessment, clinical examination was a better modality for primary, while Colour Doppler was better for axillary lymph node evaluation.
Colour Doppler-An Evaluation Tool for Assessment of Breast Tumour Size, Axillary Lymph Node Size and Chemotherapeutic Response
doi:10.11648/j.jctr.20140202.11
Journal of Cancer Treatment and Research
2014-01-01
© Science Publishing Group
Rashmi Singh
Govardhan H. B.
Satyajt Pradhan
Anand Kumar
R. C. Shukla
U. P. Shahi
L. M. Agrawal
Colour Doppler-An Evaluation Tool for Assessment of Breast Tumour Size, Axillary Lymph Node Size and Chemotherapeutic Response
2
2
15
15
2014-01-01
2014-01-01
10.11648/j.jctr.20140202.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140202.11
© Science Publishing Group
Vertebral Giant Cell Tumor: Diagnosis Difficulties and Therapeutics’ Challenges
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140202.12
Giant cell tumor remains one of the most controversial and discussed bone tumors. Its diagnosis may be very difficult especially in vertebral localization as it requires a careful study of the pathology tissue. The authors report a series of four patients, treated in the MT Kassab orthopaedic Institute for vertebral giant cell tumor (GCT), with different clinical presentation and therapeutic strategies. By presenting those cases we point to surgical and medical treatments’ difficulties and the challenge of avoiding local recurrence and distant metastasis of this tumor.
Giant cell tumor remains one of the most controversial and discussed bone tumors. Its diagnosis may be very difficult especially in vertebral localization as it requires a careful study of the pathology tissue. The authors report a series of four patients, treated in the MT Kassab orthopaedic Institute for vertebral giant cell tumor (GCT), with different clinical presentation and therapeutic strategies. By presenting those cases we point to surgical and medical treatments’ difficulties and the challenge of avoiding local recurrence and distant metastasis of this tumor.
Vertebral Giant Cell Tumor: Diagnosis Difficulties and Therapeutics’ Challenges
doi:10.11648/j.jctr.20140202.12
Journal of Cancer Treatment and Research
2014-06-17
© Science Publishing Group
Kherfani Abdelhakim
Amri Khalil
Hachem Mahjoub
Abid Leila
Bouaziz Mouna
Mestiri Mondher
Vertebral Giant Cell Tumor: Diagnosis Difficulties and Therapeutics’ Challenges
2
2
20
20
2014-06-17
2014-06-17
10.11648/j.jctr.20140202.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140202.12
© Science Publishing Group
Huge Metastatic Multicystic Ovarian Cancer with Liver Involvement: A Case Report
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140203.11
Introduction: Ovarian cancers are gynaecological malignancies described as the most lethal because they often present at the advanced stages. Metastasis to the liver parenchyma occurs in stage IVB disease. The diaphram is a tumour sanctuary site as most deposits are missed during cytoreductive surgeries and chemotherapy. Materials and method: This is a case presentation of a 39 year old lady with recurrent huge multicystic ovarian cancer with liver and diaphragmatic involvement. Abdominal ultrasound scan and a CT-scan were done amongst other investigations. This patient was co-managed by the Hepato-Pancreato-Biliary surgeons, Cardiothoracic Surgeons and the Gynaecologic oncologist. She had cytoreductive surgery and adjuvant chemotherapy. Conclusion: Diaphragmatic involvement from ovarian tumour is rare and represents an advanced disease. The superiority of CT-scan over abdominal ultrasound scan in this case is incontrovertible. A multidisciplinary approach is an important cornerstone in it’s management.
Introduction: Ovarian cancers are gynaecological malignancies described as the most lethal because they often present at the advanced stages. Metastasis to the liver parenchyma occurs in stage IVB disease. The diaphram is a tumour sanctuary site as most deposits are missed during cytoreductive surgeries and chemotherapy. Materials and method: This is a case presentation of a 39 year old lady with recurrent huge multicystic ovarian cancer with liver and diaphragmatic involvement. Abdominal ultrasound scan and a CT-scan were done amongst other investigations. This patient was co-managed by the Hepato-Pancreato-Biliary surgeons, Cardiothoracic Surgeons and the Gynaecologic oncologist. She had cytoreductive surgery and adjuvant chemotherapy. Conclusion: Diaphragmatic involvement from ovarian tumour is rare and represents an advanced disease. The superiority of CT-scan over abdominal ultrasound scan in this case is incontrovertible. A multidisciplinary approach is an important cornerstone in it’s management.
Huge Metastatic Multicystic Ovarian Cancer with Liver Involvement: A Case Report
doi:10.11648/j.jctr.20140203.11
Journal of Cancer Treatment and Research
2014-06-30
© Science Publishing Group
Ngim, Ogbu Ewezu
Ago, Boniface Uji
Ogbudu Stephen
Nwagboso Chima
Echei Chidiebere
Etiuma, Anietimfom Umoh
Bassey, Okon Odokwo
Ndoma-Egba Rowland
Huge Metastatic Multicystic Ovarian Cancer with Liver Involvement: A Case Report
2
3
26
26
2014-06-30
2014-06-30
10.11648/j.jctr.20140203.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140203.11
© Science Publishing Group
Clinical Significance of HOX11L2 and HOX11 Gene Expression in T-ALL Patients
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140203.12
Objective: The aim of this study was to determine the prognostic value of two structurally related homeobox genes TLX1/HOX11 and TLX3/HOX11L2 on the clinical outcome of T-ALL patients. Material and Methods: The study included 28 newly diagnosed T-ALL patients. HOX11L2 and HOX11 gene expression were detected by real time PCR. Patients received treatment according to the ALL BFM-90 protocol. Results: Of 28 patients, 8(28.6%) expressed HOX11L2 and 4(14.3%) expressed HOX11.The overall survival of patients with HOX11L2 expression was lower than of the patients without HOX11L2 expression (log-rank P<0.025). As regards HOX11 expression, a statistically significant difference in clinical outcome was found, where HOX11 expression conferred a prognostic advantage (p< 0.001). Conclusion: the present study was showed that the outcome of HOX11L2 and HOX11 expression differs, with poor outcome for patients with HOX11l2-expression. Future molecular diagnostics may make use of such leukemia-specific markers as HOX11L2 and HOX11 to detect minimal residual disease.
Objective: The aim of this study was to determine the prognostic value of two structurally related homeobox genes TLX1/HOX11 and TLX3/HOX11L2 on the clinical outcome of T-ALL patients. Material and Methods: The study included 28 newly diagnosed T-ALL patients. HOX11L2 and HOX11 gene expression were detected by real time PCR. Patients received treatment according to the ALL BFM-90 protocol. Results: Of 28 patients, 8(28.6%) expressed HOX11L2 and 4(14.3%) expressed HOX11.The overall survival of patients with HOX11L2 expression was lower than of the patients without HOX11L2 expression (log-rank P<0.025). As regards HOX11 expression, a statistically significant difference in clinical outcome was found, where HOX11 expression conferred a prognostic advantage (p< 0.001). Conclusion: the present study was showed that the outcome of HOX11L2 and HOX11 expression differs, with poor outcome for patients with HOX11l2-expression. Future molecular diagnostics may make use of such leukemia-specific markers as HOX11L2 and HOX11 to detect minimal residual disease.
Clinical Significance of HOX11L2 and HOX11 Gene Expression in T-ALL Patients
doi:10.11648/j.jctr.20140203.12
Journal of Cancer Treatment and Research
2014-07-14
© Science Publishing Group
Said H. Abdu
Doaa Shahin
Mohamed R. El-Shanshory
Hoda A. Salem
Eman A. Amer
Mohamed M. El-Shebeiny
Clinical Significance of HOX11L2 and HOX11 Gene Expression in T-ALL Patients
2
3
32
32
2014-07-14
2014-07-14
10.11648/j.jctr.20140203.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140203.12
© Science Publishing Group
Outcome of Chemotherapy for Adult Soft Tissue Sarcomas in Jos, North Central Nigeria
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140204.11
Background: Soft tissue sarcomas (STS) have a poor response to chemotherapy and reports have documented a 20% response rate. Chemotherapeutic regimens have evolved from the use of multiple drug combinations which were thought to be more efficacious, to high doses of single agent chemotherapy and targeted therapies. Predicting the response to chemotherapy in soft tissue sarcomas is difficult because even tumours of the same class exhibit different patterns of responsiveness to the same drugs. Single agent Adriamycin chemotherapy for soft tissue sarcomas is cheap and reputably gives comparable treatment outcomes to combination therapies. This study was therefore aimed at determining the outcome of management of soft tissue sarcomas with single agent Adriamycin chemotherapy. Patients and Method: This was a prospective analysis of consecutive patients managed for STS with single agent Adriamycin at the Jos University Teaching Hospital from January 2000 to December 2009.Results: A total of 89 adult soft tissue sarcomas were managed in 49 males and 40 females (M: F=1.2:1). The mean age of the study population was 37.4 +/- 12.6 with age range of 18 to 85years.Forty patients (44.9%) could afford chemotherapy with single agent Adriamycin and formed the basis of this study while 49 (53.1%) could not afford chemotherapy. All the tumours were more than 5cm in size at presentation. Rhabdomyosarcoma was seen in 17 patients (42.5%), fibrosarcoma in 14 (35%), liposarcoma and dermatofibrosarcoma 4 (10% ) each and one patient (2.5% ) had synovial sarcoma. Response to chemotherapy was seen in seven patients (17.5%) and this was noticed within six weeks of chemotherapy. Conclusion: Response to chemotherapy with single agent Adriamycin for the treatment of soft tissue sarcomas is very poor and it is difficult to predict which patient will respond to this therapy in our setting. We therefore suggest that all patients with STS on single agent Adriamycin in resource scarce settings should have their treatment discontinued or changed to other chemotherapeutic combinations if there is no response to chemotherapy after six weeks.
Background: Soft tissue sarcomas (STS) have a poor response to chemotherapy and reports have documented a 20% response rate. Chemotherapeutic regimens have evolved from the use of multiple drug combinations which were thought to be more efficacious, to high doses of single agent chemotherapy and targeted therapies. Predicting the response to chemotherapy in soft tissue sarcomas is difficult because even tumours of the same class exhibit different patterns of responsiveness to the same drugs. Single agent Adriamycin chemotherapy for soft tissue sarcomas is cheap and reputably gives comparable treatment outcomes to combination therapies. This study was therefore aimed at determining the outcome of management of soft tissue sarcomas with single agent Adriamycin chemotherapy. Patients and Method: This was a prospective analysis of consecutive patients managed for STS with single agent Adriamycin at the Jos University Teaching Hospital from January 2000 to December 2009.Results: A total of 89 adult soft tissue sarcomas were managed in 49 males and 40 females (M: F=1.2:1). The mean age of the study population was 37.4 +/- 12.6 with age range of 18 to 85years.Forty patients (44.9%) could afford chemotherapy with single agent Adriamycin and formed the basis of this study while 49 (53.1%) could not afford chemotherapy. All the tumours were more than 5cm in size at presentation. Rhabdomyosarcoma was seen in 17 patients (42.5%), fibrosarcoma in 14 (35%), liposarcoma and dermatofibrosarcoma 4 (10% ) each and one patient (2.5% ) had synovial sarcoma. Response to chemotherapy was seen in seven patients (17.5%) and this was noticed within six weeks of chemotherapy. Conclusion: Response to chemotherapy with single agent Adriamycin for the treatment of soft tissue sarcomas is very poor and it is difficult to predict which patient will respond to this therapy in our setting. We therefore suggest that all patients with STS on single agent Adriamycin in resource scarce settings should have their treatment discontinued or changed to other chemotherapeutic combinations if there is no response to chemotherapy after six weeks.
Outcome of Chemotherapy for Adult Soft Tissue Sarcomas in Jos, North Central Nigeria
doi:10.11648/j.jctr.20140204.11
Journal of Cancer Treatment and Research
2014-08-08
© Science Publishing Group
Misauno M. A.
Ode M.B.
Shitta A.H.
Nwadiaro H.C.
Outcome of Chemotherapy for Adult Soft Tissue Sarcomas in Jos, North Central Nigeria
2
4
36
36
2014-08-08
2014-08-08
10.11648/j.jctr.20140204.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140204.11
© Science Publishing Group
Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140204.12
PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule.
PURPOSE: In our study we compared low-dose gemcitabine-based chemoradiotherapy with cisplatin-based chemoradiotherapy as regards response rate, survival and toxicity profile in locally advanced head and neck cancer. Methodology: sixty patients with locally advanced head and neck cancer were included in this prospective comparative randomized study, in the period from January 2011 to September 2013. Results: The patients were treated in two randomized groups; each of them included 30 patients. In gemcitabine arm (group A), 42.3% of the patients had stage III, and 57.7% of them had stage IVa while 48.15% of the patients of cisplatin arm (group B) had stage III and 51.85% had stage IVa. The median duration of response in group A was 21 months, while in group B it was 23 months. The degree of response had a statistically significant effect on survival in group B patients. It was evident in patients who achieved partial response (PR) that showed lower survival than those with (CR). Conclusion: Gemcitabine has comparable radiosensitizing effect with acceptable toxicity profile and can be used as a radiosensitizer in head and neck cancers especially when cisplatin cannot be used. We recommend further studies to establish its rule.
Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer
doi:10.11648/j.jctr.20140204.12
Journal of Cancer Treatment and Research
2014-08-27
© Science Publishing Group
Elsayed M Ali
Emad Eldin Nabil
Ashraf Elyamany
Ahmed M. Maklad
Ahmed Gaber Abdelraheem
Comparative Study of Gemcitabine Versus Cisplatin Concurrent with Radiotherapy for Locally Advanced Head and Neck Cancer
2
4
44
44
2014-08-27
2014-08-27
10.11648/j.jctr.20140204.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140204.12
© Science Publishing Group
Gorham’s Disease that Gave Response to Radiotherapy
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140205.11
Background: Gorham’s disease is a disorder that results as destruction and resorption of osseous matrix and is characterized by proliferation of vascular channels. We here reported a rare case of Gorham’s disease that gave response to radiotherapy. Our aim is to remind the clinicians about this rare entity, and to discuss the etiopathology, clinical presentation and treatment options for patients with Gorham’s disease. Case Report: 32 years old male patient had admitted to neurosurgery department for pain, weakness and limitation of motion at the head and neck. Osteolysis was detected at the bodies of 1, 2 and 3. vertebrae. After a number of examinations and excisional biopsy, the patient was diagnosed as Gorham’s disease. Cervical stabilization was made but after 3 years, the patient’s complaints had occurred again and a restabilization was made. 2 years after; with increased complaints, the patient was send to our clinic for consultation and radiotherapy (RT) was applied to the destructive parts of the bones. 2 months after RT, the patients’ complaints had a significant decrease both clinically and radiologically. Conclusion: Gorham’s disease can be seen in both men,women and at any age group, although most cases are diagnosed before the age of 40 years. No familial predisposition has been found. The disease may affect the appendicular or the axial skeleton. The exact nature of the disease process is unknown. The medical treatment for Gorham’s disease includes radiation therapy, anti-osteoclastic medications (bisphosphonates), and alpha-2b interferon. As laboratory studies are usually within normal limits in most cases, diagnosis can often be delayed. By the light of clinical findings with characteristic radiographic and histopathological findings, an early diagnosis can be possible.
Background: Gorham’s disease is a disorder that results as destruction and resorption of osseous matrix and is characterized by proliferation of vascular channels. We here reported a rare case of Gorham’s disease that gave response to radiotherapy. Our aim is to remind the clinicians about this rare entity, and to discuss the etiopathology, clinical presentation and treatment options for patients with Gorham’s disease. Case Report: 32 years old male patient had admitted to neurosurgery department for pain, weakness and limitation of motion at the head and neck. Osteolysis was detected at the bodies of 1, 2 and 3. vertebrae. After a number of examinations and excisional biopsy, the patient was diagnosed as Gorham’s disease. Cervical stabilization was made but after 3 years, the patient’s complaints had occurred again and a restabilization was made. 2 years after; with increased complaints, the patient was send to our clinic for consultation and radiotherapy (RT) was applied to the destructive parts of the bones. 2 months after RT, the patients’ complaints had a significant decrease both clinically and radiologically. Conclusion: Gorham’s disease can be seen in both men,women and at any age group, although most cases are diagnosed before the age of 40 years. No familial predisposition has been found. The disease may affect the appendicular or the axial skeleton. The exact nature of the disease process is unknown. The medical treatment for Gorham’s disease includes radiation therapy, anti-osteoclastic medications (bisphosphonates), and alpha-2b interferon. As laboratory studies are usually within normal limits in most cases, diagnosis can often be delayed. By the light of clinical findings with characteristic radiographic and histopathological findings, an early diagnosis can be possible.
Gorham’s Disease that Gave Response to Radiotherapy
doi:10.11648/j.jctr.20140205.11
Journal of Cancer Treatment and Research
2014-09-16
© Science Publishing Group
Sule Karabulut Gul
Ahmet Fatih Oruc
Duygu Gedik
Hakan Levent Gul
Atınc Aksu
Alpaslan Mayadagli
Gorham’s Disease that Gave Response to Radiotherapy
2
5
47
47
2014-09-16
2014-09-16
10.11648/j.jctr.20140205.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140205.11
© Science Publishing Group
Striking Regression of Temporal Lobe Necrosis Following Radiotherapy for Nasopharyngeal Carcinoma in a Clinical trial of Anti-Mycobacterium Therapy
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140205.12
The mechanism of radiation-induced delayed brain injuries remains poorly understood, and few treatment options are available. The aim of this study was to investigate whether temporal lobe necrosis can be reversed by anti-mycobacterium therapy (AMT). We conducted this prospective, controlled study in southern China. Ten patients with symptomatic delayed radiation injury were monitored during AMT and compared with a control group of 11 patients who received current standard therapies. Activities of daily living were assessed by the Barthel Index (BI) at study entry and after 2 years of therapy. Magnetic resonance imaging (MRI) was performed before treatment, and changes were monitored during the study. Kaplan–Meier analysis was employed to delineate time-related mortality. A significant treatment effect was observed in the AMT group. The patients’ headaches, seizures, dizziness, and cognitive deterioration rapidly improved. BI improved in the AMT treatment group compared with the control group after 2 years (Mann–Whitney U test; P=0•001). Abnormalities of the temporal lobes, observed by MRI, markedly decreased over time in eight patients, whereas in the control group significant BI deterioration was observed (Wilcoxon signed-rank test; P=0•003) and the patients did not show favorable MRI changes. By 24 months, there was a significant difference between the AMT and control groups with respect to survival time (log-rank test; P=0•011). The results of the present study suggest that radiation necrosis of the brain can be successfully managed by AMT. These findings must be confirmed in large, double-blind, randomized clinical trials.
The mechanism of radiation-induced delayed brain injuries remains poorly understood, and few treatment options are available. The aim of this study was to investigate whether temporal lobe necrosis can be reversed by anti-mycobacterium therapy (AMT). We conducted this prospective, controlled study in southern China. Ten patients with symptomatic delayed radiation injury were monitored during AMT and compared with a control group of 11 patients who received current standard therapies. Activities of daily living were assessed by the Barthel Index (BI) at study entry and after 2 years of therapy. Magnetic resonance imaging (MRI) was performed before treatment, and changes were monitored during the study. Kaplan–Meier analysis was employed to delineate time-related mortality. A significant treatment effect was observed in the AMT group. The patients’ headaches, seizures, dizziness, and cognitive deterioration rapidly improved. BI improved in the AMT treatment group compared with the control group after 2 years (Mann–Whitney U test; P=0•001). Abnormalities of the temporal lobes, observed by MRI, markedly decreased over time in eight patients, whereas in the control group significant BI deterioration was observed (Wilcoxon signed-rank test; P=0•003) and the patients did not show favorable MRI changes. By 24 months, there was a significant difference between the AMT and control groups with respect to survival time (log-rank test; P=0•011). The results of the present study suggest that radiation necrosis of the brain can be successfully managed by AMT. These findings must be confirmed in large, double-blind, randomized clinical trials.
Striking Regression of Temporal Lobe Necrosis Following Radiotherapy for Nasopharyngeal Carcinoma in a Clinical trial of Anti-Mycobacterium Therapy
doi:10.11648/j.jctr.20140205.12
Journal of Cancer Treatment and Research
2014-09-29
© Science Publishing Group
Yanqing Feng
Weixi Zhang
Xi Chen
Zhenhua Gao
Minying Zheng
Ning Guo
Fan Huang
Ke Ma
Striking Regression of Temporal Lobe Necrosis Following Radiotherapy for Nasopharyngeal Carcinoma in a Clinical trial of Anti-Mycobacterium Therapy
2
5
55
55
2014-09-29
2014-09-29
10.11648/j.jctr.20140205.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140205.12
© Science Publishing Group
Incidental Prostate Cancer: Predictors of Progression and Strategies of Management Based on Prostate-Specific Antigen
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140206.11
We studied predictors for the progression of incidental prostate cancer (PCa) to optimize the management strategies that are still controversial in the era of prostate-specific antigen (PSA). We performed advanced transurethral resection of the prostate (TURP) in 995 patients with benign prostate hyperplasia (BPH). Of these, 226 patients (22.7%) had incidental PCa. Included in the present study were 146 patients followed up for two years or longer. In the treated group of 26 patients whose PSA elevated, we performed radical transurethral resection of PCa (TURPCa) in 23 patients, palliative TURP in one, and endocrine therapy in two. Between the observed and treated groups, statistical differences were noted in PSA related parameters: preoperative PSA (Pre PSA), PSA three months after surgery (Post PSA), % Post PSA/Pre PSA (%PSA ratio), and PSA density (PSAD). No differences were noted in the clinical stage (T1a, T1b) and Gleason scores. Of 23 patients underwent radical TURPCa, one had pT0 disease, one showed PSA failure, and 19 had stable PSA. It may be rational and practical to decide the treatment strategy of incidental PCa based on PSA changes before and after TURP rather than Gleason scores or clinical stages.
We studied predictors for the progression of incidental prostate cancer (PCa) to optimize the management strategies that are still controversial in the era of prostate-specific antigen (PSA). We performed advanced transurethral resection of the prostate (TURP) in 995 patients with benign prostate hyperplasia (BPH). Of these, 226 patients (22.7%) had incidental PCa. Included in the present study were 146 patients followed up for two years or longer. In the treated group of 26 patients whose PSA elevated, we performed radical transurethral resection of PCa (TURPCa) in 23 patients, palliative TURP in one, and endocrine therapy in two. Between the observed and treated groups, statistical differences were noted in PSA related parameters: preoperative PSA (Pre PSA), PSA three months after surgery (Post PSA), % Post PSA/Pre PSA (%PSA ratio), and PSA density (PSAD). No differences were noted in the clinical stage (T1a, T1b) and Gleason scores. Of 23 patients underwent radical TURPCa, one had pT0 disease, one showed PSA failure, and 19 had stable PSA. It may be rational and practical to decide the treatment strategy of incidental PCa based on PSA changes before and after TURP rather than Gleason scores or clinical stages.
Incidental Prostate Cancer: Predictors of Progression and Strategies of Management Based on Prostate-Specific Antigen
doi:10.11648/j.jctr.20140206.11
Journal of Cancer Treatment and Research
2014-12-15
© Science Publishing Group
Masaru Morita
Takeshi Matsuura
Incidental Prostate Cancer: Predictors of Progression and Strategies of Management Based on Prostate-Specific Antigen
2
6
60
60
2014-12-15
2014-12-15
10.11648/j.jctr.20140206.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140206.11
© Science Publishing Group
Advanced Prostate Cancer Presenting as Epistaxis Only: A Case Report and Literature Review
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140206.12
Although Prostate cancer is the most frequently diagnosed cancer among men globally, its primary presentation as Epistaxis alone is quit uncommon. Epistaxis has numerous causes and hence poses early diagnostic challenge. We report a case of 68 year old man who presented with recurrent epistaxis as the main complaint .He was thoroughly evaluated and concluded to have a background asymptomatic advanced prostate cancer with isolated thrombocytopenia. He responded to blood transfusion and combined therapy form of Anti-androgen Deprivation Therapy. High index of suspicion is of paramount importance towards achieving early diagnosis of this unusual presentation.
Although Prostate cancer is the most frequently diagnosed cancer among men globally, its primary presentation as Epistaxis alone is quit uncommon. Epistaxis has numerous causes and hence poses early diagnostic challenge. We report a case of 68 year old man who presented with recurrent epistaxis as the main complaint .He was thoroughly evaluated and concluded to have a background asymptomatic advanced prostate cancer with isolated thrombocytopenia. He responded to blood transfusion and combined therapy form of Anti-androgen Deprivation Therapy. High index of suspicion is of paramount importance towards achieving early diagnosis of this unusual presentation.
Advanced Prostate Cancer Presenting as Epistaxis Only: A Case Report and Literature Review
doi:10.11648/j.jctr.20140206.12
Journal of Cancer Treatment and Research
2015-01-04
© Science Publishing Group
Usman Mohammed Tela
Audu Abdullahi Bukar
Mala Bukar Sandabe
Theophilus Maksha Dabkana
Alhaji Bukar Musa
Abubakar Sadiq Adamu
Advanced Prostate Cancer Presenting as Epistaxis Only: A Case Report and Literature Review
2
6
63
63
2015-01-04
2015-01-04
10.11648/j.jctr.20140206.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20140206.12
© Science Publishing Group
“Every Contact Leaves Its Trace”-Insight into Recent Advances of Forensic Odontology
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150301.11
Forensic dentistry plays a major role in the identification of those individuals who cannot be identified visually or by other means. The unique nature of our dental anatomy and the placement of custom restorations ensure accuracy when the techniques are correctly employed. This article briefs an overview of some of the traditional and upcoming techniques in this fascinating field.
Forensic dentistry plays a major role in the identification of those individuals who cannot be identified visually or by other means. The unique nature of our dental anatomy and the placement of custom restorations ensure accuracy when the techniques are correctly employed. This article briefs an overview of some of the traditional and upcoming techniques in this fascinating field.
“Every Contact Leaves Its Trace”-Insight into Recent Advances of Forensic Odontology
doi:10.11648/j.jctr.20150301.11
Journal of Cancer Treatment and Research
2015-02-15
© Science Publishing Group
Sumalatha S.
Padmaja S.
Prafulla Thumati
“Every Contact Leaves Its Trace”-Insight into Recent Advances of Forensic Odontology
3
1
7
7
2015-02-15
2015-02-15
10.11648/j.jctr.20150301.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150301.11
© Science Publishing Group
Utilization of a Self- Care Educational Program for Alleviating Chemotherapy Induced Physical Side Effects
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150301.12
Breast cancer is the most common cancer among women of both developed and developing countries. It is one of the leading causes of deaths in females. The aim of this study was to evaluate the utilization of a self-care educational program for alleviating chemotherapy induced physical side effects. A quasi – experimental design was used. The study was conducted at outpatient clinics at Oncology Center at Mansoura university Hospital. The study subjects included eighty mastectomised women receiving parenteral adjuvant chemotherapy for the first time. Subjects were divided randomly into two groups: the intervention group obtained a self- care educational program while the control group received the routine care. Three tools were used for data collection (An interview questionnaire sheet, Modified memorial (chemotherapy) symptoms assessment scale& Modified self- care diary scale). Study results showed that self- care educational program is effective on alleviating physical side effects of chemotherapy. The study recommended the important of teaching such educational program in all Egyptian Oncology Centers for alleviating such chemotherapy induced physical side effects.
Breast cancer is the most common cancer among women of both developed and developing countries. It is one of the leading causes of deaths in females. The aim of this study was to evaluate the utilization of a self-care educational program for alleviating chemotherapy induced physical side effects. A quasi – experimental design was used. The study was conducted at outpatient clinics at Oncology Center at Mansoura university Hospital. The study subjects included eighty mastectomised women receiving parenteral adjuvant chemotherapy for the first time. Subjects were divided randomly into two groups: the intervention group obtained a self- care educational program while the control group received the routine care. Three tools were used for data collection (An interview questionnaire sheet, Modified memorial (chemotherapy) symptoms assessment scale& Modified self- care diary scale). Study results showed that self- care educational program is effective on alleviating physical side effects of chemotherapy. The study recommended the important of teaching such educational program in all Egyptian Oncology Centers for alleviating such chemotherapy induced physical side effects.
Utilization of a Self- Care Educational Program for Alleviating Chemotherapy Induced Physical Side Effects
doi:10.11648/j.jctr.20150301.12
Journal of Cancer Treatment and Research
2015-07-22
© Science Publishing Group
Amina Mohamed Rashad El-Nemer
Maha Ibrahim Ismail El-Zafrani
Hanan El-Sayed Mohamed El-Sayed
Om Hashim Mahmoud Mahmoud Saadoon
Utilization of a Self- Care Educational Program for Alleviating Chemotherapy Induced Physical Side Effects
3
1
16
16
2015-07-22
2015-07-22
10.11648/j.jctr.20150301.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150301.12
© Science Publishing Group
Endometrial Curettage When and for Who
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150302.11
In this study, the histopathological diagnoses pertaining to curettage material and the clinical necessity and results of endometrial curettagein age groups of patients in our region who had curettage due to abnormal uterine bleeding were studied. Thehistopathological diagnoses of patients with the above-mentioned criteria were scanned, excluding those related to pregnancy. 409 cases were re-examined and evaluated by a group consisting of three pathologists. Diagnoses were classified into 10 different groups. According to this classification system, out of the total number of cases, 100 were defined as endometrial polyp (24.4%), 72 cases as secretory endometrium (17.6%), 59 cases as proliferative endometrium (14.4%), 51 cases as stromal/glandular degeneration (12.5%), 32 cases as irregular proliferation (7.8%), 26 cases as insufficient (6.4%), 22 cases as chronic endometritis (5.6%), 18 cases as decidualization (4.4%), 17 cases as endometrial hyperplasia (complex atypical)/ adenocarcinoma (4.2%), and 12 cases as others (inactive, atrophic, basal and menstrual endometrium) (2.9%). The average age of the 409 cases was 44.8±7.8. Upon evaluation of curettage due to abnormal uterine bleeding in the approximate 3 year period in our region, and taking into consideration the age distribution, it was observed that the clinical pre-diagnoses of patients especially with endometrial polyps and precancerous lesions were coherent with the corresponding histopathological diagnoses.
In this study, the histopathological diagnoses pertaining to curettage material and the clinical necessity and results of endometrial curettagein age groups of patients in our region who had curettage due to abnormal uterine bleeding were studied. Thehistopathological diagnoses of patients with the above-mentioned criteria were scanned, excluding those related to pregnancy. 409 cases were re-examined and evaluated by a group consisting of three pathologists. Diagnoses were classified into 10 different groups. According to this classification system, out of the total number of cases, 100 were defined as endometrial polyp (24.4%), 72 cases as secretory endometrium (17.6%), 59 cases as proliferative endometrium (14.4%), 51 cases as stromal/glandular degeneration (12.5%), 32 cases as irregular proliferation (7.8%), 26 cases as insufficient (6.4%), 22 cases as chronic endometritis (5.6%), 18 cases as decidualization (4.4%), 17 cases as endometrial hyperplasia (complex atypical)/ adenocarcinoma (4.2%), and 12 cases as others (inactive, atrophic, basal and menstrual endometrium) (2.9%). The average age of the 409 cases was 44.8±7.8. Upon evaluation of curettage due to abnormal uterine bleeding in the approximate 3 year period in our region, and taking into consideration the age distribution, it was observed that the clinical pre-diagnoses of patients especially with endometrial polyps and precancerous lesions were coherent with the corresponding histopathological diagnoses.
Endometrial Curettage When and for Who
doi:10.11648/j.jctr.20150302.11
Journal of Cancer Treatment and Research
2015-03-09
© Science Publishing Group
Aslıhan Duman
Ferah Tuncel Daloğlu
Yeliz Arman Karakaya
Aysun Aras
Endometrial Curettage When and for Who
3
2
21
21
2015-03-09
2015-03-09
10.11648/j.jctr.20150302.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150302.11
© Science Publishing Group
A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150302.12
New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
New approaches to curb developmental and end-stage production expenses, whilst generating a safe and effective treatment for cancer, resulting in lower cost for the patient and healthcare system, are warranted. A bioassay-guided fractionation of a Solanum plant, S. sodomaeum, to a standardized extract can be classified as a new drug. It is shown that a specific standardized plant extract, BEC, containing a given concentration of a target efficacious and safe compound, solamargine, is an acceptable anticancer and less costly chemotherapeutic reality.
A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
doi:10.11648/j.jctr.20150302.12
Journal of Cancer Treatment and Research
2015-03-24
© Science Publishing Group
Aruba Cham
Kai Cham
Tania Chase
Bill Cham
A Standardized Plant Extract Containing a Target Compound is Acceptable as a Potent Therapeutic Entity: Relevance to BEC and Solamargine, a Topical Clinical Formulation CuradermBEC5
3
2
27
27
2015-03-24
2015-03-24
10.11648/j.jctr.20150302.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150302.12
© Science Publishing Group
A Néoplasma of the Breast Revealed by a Bilateral Choriodal Metasytasis
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.11
The uveals metastases are the most frequent malignant tumours of the eye, 10 times more than the melanoma. Their rate of which has occurred is estimated in the recent literature between 2 and 38%, their period of apparition are more often at the final stage of the neoplasma. Our work present the rare case of 40 year old patient, in quite condition general, addressed to our consultation for bilateral retinal detachment, whose clinical exams, angiographic, B-scan, CT-tomography and mammography make it possible to keep the diagnosis of bilateral uveal metastasis revealing an unrecognised néoplasma of the breast to the stage of bony and ganglial metastasis. Knowing the severe prognosis of uveal metastasis, a suitable treatment is started trying as well as possible to preserve the visual prognosis in this patient suffering of cancer.
The uveals metastases are the most frequent malignant tumours of the eye, 10 times more than the melanoma. Their rate of which has occurred is estimated in the recent literature between 2 and 38%, their period of apparition are more often at the final stage of the neoplasma. Our work present the rare case of 40 year old patient, in quite condition general, addressed to our consultation for bilateral retinal detachment, whose clinical exams, angiographic, B-scan, CT-tomography and mammography make it possible to keep the diagnosis of bilateral uveal metastasis revealing an unrecognised néoplasma of the breast to the stage of bony and ganglial metastasis. Knowing the severe prognosis of uveal metastasis, a suitable treatment is started trying as well as possible to preserve the visual prognosis in this patient suffering of cancer.
A Néoplasma of the Breast Revealed by a Bilateral Choriodal Metasytasis
doi:10.11648/j.jctr.20150303.11
Journal of Cancer Treatment and Research
2015-04-10
© Science Publishing Group
Souhail Hassane
Ifrkhas Said
Laktaoui Abdelkader
A Néoplasma of the Breast Revealed by a Bilateral Choriodal Metasytasis
3
3
31
31
2015-04-10
2015-04-10
10.11648/j.jctr.20150303.11
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.11
© Science Publishing Group
Bevacizumab Induced Cardiomyopathy in a Patient with Adult Congenital Heart Disease: A Case Report and Brief Review
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.12
Background: Cardiac dysfunction is an unusual but documented side effect of many forms of antineoplastic therapy. Bevacizumab is a novel antineoplastic agent that inhibits VEGF-A with a low reported incidence of cardiotoxicity (1.7 - 3%) derived primarily from clinical trials of women with breast cancer which captured adverse events of symptomatic heart failure. Subsequent studies suggest the incidence of asymptomatic decline in cardiac function may be closer to 20%. Untreated declines in cardiac function are associated with increased morbidity and mortality, early recognition and treatment can improve outcomes. Case Report: Here we describe a case of a 51 year old male being treated with Bevacizumab for metastatic neuroendocrine cancer of the colon who developed a severe asymptomatic decline in cardiac function. With interruption of Bevacizumab and implementation of heart failure therapy his cardiac function returned to baseline. Conclusion: Early recognition and application of heart failure disease modifying therapy can decrease the risk and improve the likelihood of recovery in cases of chemotherapy induced cardiac dysfunction. Baseline cardiac testing and standardized surveillance can increase the opportunities for early intervention and may improve long term outcomes.
Background: Cardiac dysfunction is an unusual but documented side effect of many forms of antineoplastic therapy. Bevacizumab is a novel antineoplastic agent that inhibits VEGF-A with a low reported incidence of cardiotoxicity (1.7 - 3%) derived primarily from clinical trials of women with breast cancer which captured adverse events of symptomatic heart failure. Subsequent studies suggest the incidence of asymptomatic decline in cardiac function may be closer to 20%. Untreated declines in cardiac function are associated with increased morbidity and mortality, early recognition and treatment can improve outcomes. Case Report: Here we describe a case of a 51 year old male being treated with Bevacizumab for metastatic neuroendocrine cancer of the colon who developed a severe asymptomatic decline in cardiac function. With interruption of Bevacizumab and implementation of heart failure therapy his cardiac function returned to baseline. Conclusion: Early recognition and application of heart failure disease modifying therapy can decrease the risk and improve the likelihood of recovery in cases of chemotherapy induced cardiac dysfunction. Baseline cardiac testing and standardized surveillance can increase the opportunities for early intervention and may improve long term outcomes.
Bevacizumab Induced Cardiomyopathy in a Patient with Adult Congenital Heart Disease: A Case Report and Brief Review
doi:10.11648/j.jctr.20150303.12
Journal of Cancer Treatment and Research
2015-04-22
© Science Publishing Group
Hemalatha Narayanasamy
Nikky Bardia
Michael Fong
Luanda Grazette
Bevacizumab Induced Cardiomyopathy in a Patient with Adult Congenital Heart Disease: A Case Report and Brief Review
3
3
36
36
2015-04-22
2015-04-22
10.11648/j.jctr.20150303.12
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.12
© Science Publishing Group
The Complete Decongestive Therapy to Treat Lymphedema in Post-Breast Cancer Surgery and Its Relationships with Patients Psychological and Physical Characteristics: A Pilot Study
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.13
Background. More than 20% of women treated for breast cancer are at risk for developing lymphedema, a chronic condition that causes swelling, pain, altered appearance and reduced mobility. Complete Decongestive Therapy (CDT) is considered the gold standard to treat lymphedema. Objective. To measure lymphedema features and psychological variables in 10 post-breast cancer surgery patients at baseline, and 1, 6, and 12 months after CDT. Results. Lymphedema appeared between 0 and 6 years after breast cancer surgery. After 4 weeks in CDT treatment, the median degree of reduction was 38.73% (range, 7.45-58.39), and six months after, 49.57% (range, 11.91-82.50). Comparing patients that have had an extra reduction in arm circumferences at T3 (group 1) and patients that did not (group 2), we found: patients in group 1 showed at baseline a better psychological functioning (health-related quality of life domains, anxiety, depression, body-image vulnerability, appearance stereotyping), and higher scores in curability and severity respect to the comparison group. 12 months after the CDT, among patients of the group 1, the lymphedema is perceived as less severe and more curable compared to their perception at baseline, and dysfunctional investment in one’s appearance and anxiety scores decreased, emotional wellbeing improved. Patients in the group 2 perceived lymphedema as much more curable, but also much more severe that at baseline. Both, anxiety and dysfunctional investment in one’s appearance scores increased. Conclusions. Too often, conventional rehabilitation may not optimally match clinical resources to patients’ needs, and if our results will be confirmed, screening and independent treatment for psychological distress will be required in patients to prevent poor CDT responses.
Background. More than 20% of women treated for breast cancer are at risk for developing lymphedema, a chronic condition that causes swelling, pain, altered appearance and reduced mobility. Complete Decongestive Therapy (CDT) is considered the gold standard to treat lymphedema. Objective. To measure lymphedema features and psychological variables in 10 post-breast cancer surgery patients at baseline, and 1, 6, and 12 months after CDT. Results. Lymphedema appeared between 0 and 6 years after breast cancer surgery. After 4 weeks in CDT treatment, the median degree of reduction was 38.73% (range, 7.45-58.39), and six months after, 49.57% (range, 11.91-82.50). Comparing patients that have had an extra reduction in arm circumferences at T3 (group 1) and patients that did not (group 2), we found: patients in group 1 showed at baseline a better psychological functioning (health-related quality of life domains, anxiety, depression, body-image vulnerability, appearance stereotyping), and higher scores in curability and severity respect to the comparison group. 12 months after the CDT, among patients of the group 1, the lymphedema is perceived as less severe and more curable compared to their perception at baseline, and dysfunctional investment in one’s appearance and anxiety scores decreased, emotional wellbeing improved. Patients in the group 2 perceived lymphedema as much more curable, but also much more severe that at baseline. Both, anxiety and dysfunctional investment in one’s appearance scores increased. Conclusions. Too often, conventional rehabilitation may not optimally match clinical resources to patients’ needs, and if our results will be confirmed, screening and independent treatment for psychological distress will be required in patients to prevent poor CDT responses.
The Complete Decongestive Therapy to Treat Lymphedema in Post-Breast Cancer Surgery and Its Relationships with Patients Psychological and Physical Characteristics: A Pilot Study
doi:10.11648/j.jctr.20150303.13
Journal of Cancer Treatment and Research
2015-05-01
© Science Publishing Group
Eva Mazzotti
Roberto Bartoletti
Claudia Sebastiani
Alessandro Scoppola
Paolo Marchetti
The Complete Decongestive Therapy to Treat Lymphedema in Post-Breast Cancer Surgery and Its Relationships with Patients Psychological and Physical Characteristics: A Pilot Study
3
3
41
41
2015-05-01
2015-05-01
10.11648/j.jctr.20150303.13
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.13
© Science Publishing Group
Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.14
Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.
Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.
Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer
doi:10.11648/j.jctr.20150303.14
Journal of Cancer Treatment and Research
2015-07-05
© Science Publishing Group
Kweon Sang Moon
Joo Yeon Ji
Yoo Jin Cho
Jong Hwa Lee
Myung Sup Choi
Euishin Edmund Kim
Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer
3
3
46
46
2015-07-05
2015-07-05
10.11648/j.jctr.20150303.14
http://www.sciencepublishinggroup.com/journal/paperinfo.aspx?journalid=654&doi=10.11648/j.jctr.20150303.14
© Science Publishing Group